Stockscreener 앱 받기
47.86
0.48%
0.23
시간 외 거래:
47.86
전일 마감가:
$47.63
열려 있는:
$47.66
하루 거래량:
515.09K
Relative Volume:
0.45
시가총액:
$3.79B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-8.0572
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-3.23%
1개월 성능:
-4.66%
6개월 성능:
+5.77%
1년 성능:
+46.67%
1일 변동 폭
$47.17
$48.69
1주일 범위
$47.17
$49.90
52주 변동 폭
$29.02
$58.38
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
47.86 | 3.92B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Is PTC Therapeutics Inc. a good long term investmentSuperior returns - Autocar Professional
Pega to Announce Financial Results for the Second Quarter of 2025 and Host Conference Call and Webcast - Yahoo.co
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results - Eastern Progress
Pierre Gravier Sells 2,516 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
What drives PTC Therapeutics Inc. stock priceExceptional financial outcomes - PrintWeekIndia
What analysts say about PTC Therapeutics Inc. stockFree Capital Efficiency Planning - Autocar Professional
Edgestream Partners L.P. Makes New $418,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
William Blair Predicts Weaker Earnings for PTC Therapeutics - MarketBeat
PTC Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
William Blair Forecasts Lower Earnings for PTC Therapeutics - MarketBeat
What makes PTC Therapeutics Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru
PTC Therapeutics Advances PKU Treatment with Sepiapterin Study - TipRanks
PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors - TipRanks
Brokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $65.00 - MarketBeat
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance - GlobeNewswire Inc.
PTC Therapeutics stock gets Buy rating from UBS ahead of FDA decision - Investing.com Canada
Allspring Global Investments Holdings LLC Acquires Shares of 10,287 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Banque Pictet & Cie SA Acquires New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
PTC Therapeutics: Regulatory Catalysts and Financial Fortitude Position the Company for a Breakout Year - AInvest
PTCT FY2025 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation - Seeking Alpha
PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - inkl
EC approves PTC Thera’s Sephience for PKU - The Pharma Letter
Germany will be first launch for PTC's phenylketonuria drug - pharmaphorum
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - PR Newswire
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches - Insider Monkey
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Company Announcement - Financial Times
10 Biotech Stocks Screaming a Buy - Insider Monkey
PTC Therapeutics (PTCT): Truist Securities Initiates Coverage with 'Buy' Rating | PTCT Stock News - GuruFocus
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - MarketScreener
Truist Financial Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Gains Buy Rating with Promising Drug Pipeline | PTCT Stock News - GuruFocus
When the Price of (PTCT) Talks, People Listen - news.stocktradersdaily.com
GAMMA Investing LLC Increases Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Pallas Capital Advisors LLC Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Harbor Capital Advisors Inc. Has $2.08 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics’ SWOT analysis: biotech stock’s potential in rare disease market - Investing.com Nigeria
PTC Therapeutics’ SWOT analysis: biotech stock’s potential in rare disease market By Investing.com - Investing.com South Africa
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):